Business Context and Reporting Period
Company: Proteon Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 2, 2015
Business Context: The filing discloses a significant clinical milestone regarding the Company's investigational drug, vonapanitase (formerly PRT-201).
Key Financial Metrics
This Form 8-K is a disclosure of a material event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Clinical Milestone: The Company completed enrollment of its first Phase 3 clinical study for vonapanitase.
- Study Focus: The study evaluates the safety and efficacy of a single treatment of vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (AVF) for hemodialysis.
Guidance, Outlook, and Management Commentary
- Data Expectation: Management expects to report top-line data from the Phase 3 study in December 2016.
- Regulatory Note: The information in this Item 7.01 and the attached press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific inclusion/exclusion criteria for the Phase 3 study of vonapanitase in CKD patients.
- Confirm the timeline for the December 2016 top-line data release.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the study design.
- Check subsequent filings for updates on the study results and any impact on the Company's cash position or capital requirements.